



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/528,881	09/09/2005	Tatsuo Hoshino	21420 US C038435/0185662	4641
7590 Stephen M Haracz Bryan Cave 1290 Avenue of the Americas New York, NY 10104			EXAMINER TONGUE, LAKIA J	
			ART UNIT 1645	PAPER NUMBER
			MAIL DATE 08/08/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/528,881	Applicant(s) HOSHINO ET AL.	
	Examiner LAKIA J. TONGUE	Art Unit 1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 May 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) 1-8 and 13-15 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 9-12 and 16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 23 March 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>3/23/05</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group II claims 9-16, in the reply filed on May 5, 2008 is acknowledged.

Applicant argues that:

1) The presence of both genes is disclosed to "improve the production efficiency of vitamin B₆ drastically, thus to require election between the two components of the recited vector would require Applicant to rewrite the claim in a fundamental way, which is not permitted.

Applicant's arguments have been considered.

With regard to Point 1, the Examiner believes Applicant misinterpreted the additional election requirement. When the Examiner referred to "specific genes", the Examiner was referring to a specific organism, for example, *E. coli*. Consequently, no additional gene in the sense of pyridoxol 5'-phosphate synthase gene and D-erythrose 4-phosphate dehydrogenase gene needed to be selected. Consequently, both pyridoxol 5'-phosphate synthase gene and D-erythrose 4-phosphate dehydrogenase gene are under examination.

Claims 1-16 are pending. Claims 1-8 and 13-15 have been withdrawn from further consideration as being drawn to non-elected inventions. Claims 9-12 and 16 are currently under examination.

Information Disclosure Statement

2. The information disclosure statement (IDS) submitted on August 23, 2006 is in compliance with the provisions of 37 CFR 1.97 and has been considered. An initialed copy is attached hereto.

Specification

3. The disclosure is objected to because of the following informalities: The specification does not provide a Brief Description section to accurately describe each of the figures provided.

Appropriate correction is required.

4. The use of multiple trademarks (i.e. QIAGEN on page 5) has been noted in this application. They should be capitalized wherever it appears and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Claim Objections

5. Claims 10-12 are objected to because of the following informalities: claims 10-12 recite language of non-elected claims. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 11, 12 and 16 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 11, 12 and 16 are drawn a process for preparing vitamin b₆ by cultivating a recombinant microorganism of the genus *Sinorhizobium* which is transformed with a vector containing pyridoxol 5'-phosphate synthase gene and D-erythrose 4-phosphate dehydrogenase gene, and being capable of producing vitamin B₆ which comprises cultivating the recombinant microorganism under aerobic conditions at a pH value of about 5.0 to 9.0, at a temperature of 10°C to 40°C, and for 1 day to 15 days in a medium containing an assimilable carbon source, a digestible nitrogen source, inorganic salts, and other nutrients necessary for the growth of the microorganism, and then recovering vitamin B₆ formed and accumulated in the culture broth, wherein the pyridoxol 5'-phosphate synthase gene is derived from *Sinorhizobium meliloti* IFO 14782. Subsequent claim 16 recites wherein the recombinant microorganism is *Sinorhizobium meliloti* IFO 14782/pVK6.

Because it is not clear that cell lines possessing the properties of ***Sinorhizobium meliloti* IFO 14782 and *Sinorhizobium meliloti* IFO 14782/pVK6** are known and

Art Unit: 1645

publicly available or can be reproducibly isolated from nature without undue experimentation and because the claims require the use of a suitable deposit for patent purposes a deposit in a public repository is required. Without a publicly available deposit of the above ***Sinorhizobium meliloti* IFO 14782 and *Sinorhizobium meliloti* IFO 14782/pVK6**, one of ordinary skill in the art could not be assured of the ability to practice the invention as claimed. Exact replication of the cell line is an unpredictable event.

Applicant's referral to the deposit of ***Sinorhizobium meliloti* IFO 14782 on page 3, lines 19-25** of the specification is an insufficient assurance that all required deposits have been made and all the conditions of 37 CFR 1.801-1.809 have been met. Please note that Applicant has not made any reference to *Sinorhizobium meliloti* IFO 14782/pVK6 having met the required deposits conditions.

If the deposit has been made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by the International Depository Authority under the provisions of the Budapest Treaty and that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application. These requirements are necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State. Amendment of the specification to recite the date

Art Unit: 1645

of the deposit and the complete name and full street address of the depository is required.

If the deposits have not been made under the provisions of the Budapest Treaty, then in order to certify that the deposits comply with the criteria set forth in 37 CFR 1.801-1.809, assurances regarding availability and permanency of deposits are required. Such assurance may be in the form of an affidavit or declaration by applicants or assignees or in the form of a statement by an attorney of record who has the authority and control over the conditions of deposit over his or her signature and registration number averring:

(a) during the pendency of this application, access to the deposits will be afforded to the Commissioner upon request;

(b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application;

(c) the deposits will be maintained in the public repository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and

(d) the deposits will be replaced if they should become nonviable or non-replicable.

In addition, a deposit of biological material that is capable of self-replication either directly or indirectly must be viable at the time of deposit and during the term of deposit. Viability may be tested by the repository. The test must conclude only that the deposited material is capable of reproduction. A viability statement for each deposit of

Art Unit: 1645

biological material not made under the Budapest Treaty must be filed in the application and must contain:

- 1) The name and address of the depository;
- 2) The name and address of the depositor;
- 3) The date of deposit;
- 4) The identity of the deposit and the accession number given by the depository;
- 5) The date of the viability test;
- 6) The procedures used to obtain a sample if test is not done by the depository; and
- 7) A statement that the deposit is capable of reproduction.

As well as a statement that removes restrictions to provide access to this strain upon granting of a patent has not made, either in the instant Specification, nor in Applicant's Remarks.

One of the critical conditions of Deposit is defined in 37 CFR 1.808 requires that the deposit of biological material be made under two conditions: (A) access to the deposit will be available during pendency of the patent application making reference to the deposit to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122, and (B) with one exception, that all restrictions imposed by the depositor on the availability to the public of the deposited biological material be irrevocably removed upon the granting of the patent. Upon making this statement, the rejection under 35 USC 112, first paragraph will be withdrawn. This rejection can be obviated through perfection of the Deposit and amendment of the claims to clearly set forth the Deposited strains.

As a possible means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of each deposit.

If the deposit was made after the effective filing date of the application for patent in the United States, a verified statement is required from a person in a position to corroborate that the ***Sinorhizobium meliloti* IFO 14782 and *Sinorhizobium meliloti* IFO 14782/pVK6** described in the specification as filed is the same as that deposited in the depository. Corroboration may take the form of a showing a chain of custody from applicant to the depository coupled with corroboration that the deposit is identical to the biological material described in the specification and in the applicant's possession at the time the application was filed.

Applicant's attention is directed to In re Lundack, 773 F.2d.1216, 227 USPQ (CAFC 1985) and 37 CFR 1.801-1.809 for further information concerning deposit practice.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 9-12 and 16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 11, 12 and 16 are rendered vague and indefinite by the use of the terms "IFO 14782" and "IFO 14782/pVK611". It is unclear what is meant by said terms as no structural or biological properties are conveyed by said term. What constitutes "IFO 14782" and "IFO 14782/pVK611"? Are they accession numbers or some other type of

Art Unit: 1645

laboratory designation? If the former is true, Applicant is reminded that the claims must specifically recite the depository and the accession number under which the claimed organism was deposited. As written, it is impossible to determine the metes and bounds of the claimed invention.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. Claims 9-12 and 16 are rejected under 35 U.S.C. 103(a) as obvious over Ichikawa et al. (EP 0765938) and Yocum et al. (U.S. 2005/0164335 A1).

The rejected claims are drawn to a process for preparing vitamin B₆ by cultivating a recombinant microorganism of the genus *Sinorhizobium* which is transformed with a vector containing pyridoxol 5'-phosphate synthase gene and D-erythrose 4-phosphate dehydrogenase gene, and being capable of producing vitamin B₆ which comprises cultivating the recombinant microorganism under aerobic conditions at a pH value of about 5.0 to 9.0, at a temperature of 10°C to 40°C, and for 1 day to 15 days in a medium containing an assimilable carbon source, a digestible nitrogen source, inorganic salts, and other nutrients necessary for the growth of the microorganism, and then recovering vitamin B₆ formed and accumulated in the culture broth.

Art Unit: 1645

Ichikawa et al. disclose a process for producing vitamin B₆ which comprises cultivating a microorganism belonging to the genus *Rhizobium* (former name for *Sinorhizobium*) and being capable of producing B₆ in a culture medium under aerobic conditions and separating the resulting B₆ from the fermentation broth (see page 2, lines 14-16). Ichikawa et al. disclose that *Rhizobium* are incubated in a culture medium containing assimilable carbon sources, digestible nitrogen sources, inorganic salts and other nutrients necessary for the growth of the microorganism (see page 2, lines 21-24). Ichikawa et al. disclose that the pH of the culture medium is suitably about 5 to about 9; the temperature is about 10 to 40°C; and the cultivation time is about 1 to 14 days (see page 2, lines 28-30). Moreover, Ichikawa et al. disclose that suitable strains include but are not limited to *Rhizobium* IFO 14782 (see page 2, lines 42-46). After the cultivation, the produced vitamin B₆ may be separated from the culture broth and purified (see page 2, lines 37 and 38).

Ichikawa et al. do not specifically disclose that the claimed organism is transformed with a vector containing pyridoxol 5'-phos-phate synthase gene and D-erythrose 4-phosphate dehydrogenase gene.

Yocum et al. disclose a method of producing B₆ vitamers. Said method expresses pdxJ, which necessarily encompasses pyridoxol 5'-phos-phate synthase gene and D-erythrose 4-phosphate dehydrogenase gene (see paragraph 0014). Moreover, Yocum et al. disclose that vectors containing genes encoding pdxJ are used (see paragraph 0015).

Art Unit: 1645

It would have been obvious for one of ordinary skill in the art at the time of the invention to transform *Sinorhizobium* with a vector containing pyridoxol 5'-phosphate synthase gene and D-erythrose 4-phosphate dehydrogenase gene because all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. KSR forecloses the argument that a **specific** teaching, suggestion, or motivation is required to support a finding of obvious. See the recent Board decision *Ex parte Smith*, --USPQ2d--, slip op. at 20, (Bd. Pat. App. & Interf. June 25, 2007) (citing *KSR*, 82 USPQ2d at 1396).

Absent evidence to the contrary the genes of the prior art are the same as those organisms recited in the instant claims. The process of Ichikawa et al. necessarily encompasses *Sinorhizobium meliloti* IFO 14782/pVK611 and is necessarily capable of producing vitamin B₆.

Conclusion

9. No claim is allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAKIA J. TONGUE whose telephone number is (571)272-2921. The examiner can normally be reached on Monday-Friday 8-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LJT
7/30/08

/Robert A. Zeman/

for Lakia J. Tongue, Examiner of Art Unit 1645